PHILADELPHIA — Pennsylvania drug company Inovio Pharmaceuticals said Monday it had begun a clinical study of its experimental Zika vaccine in 160 healthy adult volunteers in Puerto Rico, where the virus outbreak has been declared a public health emergency.

In June, Inovio began a human Zika trial at three U.S. and Canadian locations and has enrolled 40 healthy adults. But Puerto Rico is the part of the U.S. hardest hit by the mosquito-borne virus; as of Friday, the American territory had reported more than 14,000 cases, including 1,244 among pregnant women.

“The rapid progression of the Zika outbreak in Puerto Rico provides an immediate and unique opportunity to assess a preventive vaccine in a real world setting,” said J. Joseph Kim, Inovio president and CEO.

“If the results are promising, we plan to meet with regulators in 2017 to map out the most efficient path forward to develop our Zika vaccine and help mitigate this widespread Zika outbreak that has expanded into the continental United States.”

Advertise with us

The Centers for Disease Control and Prevention has estimated Zika will infect more than 25 percent of the Puerto Rican population by the end of the year, Inovio said.

The study in Puerto Rico involves 80 volunteers who will receive the vaccine and 80 who will receive a placebo to evaluate the safety, tolerability, and immunogenicity of the vaccine against the mosquito-borne virus.

Inovio, headquartered in the Philadelphia-area city of Plymouth Meeting, is developing its Zika vaccine with GeneOne Life Science in South Korea and academic collaborators, including the Wistar Institute in Philadelphia.

The company expects to report results later this year on its trial that began in June. Small, early-stage studies help assess the safety and promise of an experimental vaccine but cannot prove if it really works.

To date, there are no approved vaccines or therapies for Zika virus infection. Several companies and academic groups have announced plans to develop Zika virus vaccines. Only Inovio and a U.S. government research center have begun human clinical studies, the company said.

Advertise with us

The National Institutes of Health is also studying a DNA-based vaccine rather than the traditional method using a dead or weakened virus to train the body’s immune system to recognize an infection and fight it off. Other vaccine candidates are also in development, including one developed by the Walter Reed Army Institute of Research that is scheduled for safety testing in October.

Inovio has tested its DNA-based vaccine — using DNA sequences of the Zika Virus — in mice and monkeys with positive results. The company said its vaccine induced robust antibody and T-cell responses — the immune responses necessary to fight viral infections — in animals.

Inovio’s DNA-based vaccine does not use traditional live or killed viruses, and is quicker to develop because it creates a synthetic DNA sequence in a lab that triggers the body to create the same antigens as from a killed or weakened virus, Mr. Kim said.

Zika is generally spread by the bite of two species of infected mosquito. It can also be sexually transmitted.

The Zika virus causes mild flulike symptoms in most infected people, but has been linked to an increase in babies born with microcephaly, which results in abnormally small heads and impaired brain development. Health authorities have also seen an increase in Guillain-Barre syndrome, a neurological disorder, in areas affected by Zika.

Advertise with us

Inovio’s announcement came on the same day that a pair of Zika studies made headlines.

A team of researchers from Florida State University, Johns Hopkins University and the National Institutes of Health published research showing that existing drugs — including an FDA-approved drug used to treat tapeworm — can potentially stop Zika from replicating in the body and damaging fetal brains. The team’s research may be the first to identify a therapeutic treatment for Zika.

And researchers led by Robert Tesh, a pathologist at the University of Texas Medical Branch in Galveston, found that Zika can be transmitted by a female mosquito to her eggs, eventually infecting her adult daughters.

Elsewhere, Singapore reported one of the largest single clusters outside of the Americas, confirming 50 infections. On Monday, inspectors armed with insecticide were visiting high-rise public housing buildings to look at toilets and other areas for stagnant water, according to the Agence France-Presse.

On the opposite side of the world, Disney World, Universal, SeaWorld, Busch Gardens and other theme parks in Florida said Sunday that they would begin distributing free insect repellent to visitors.

Associated Press, The Washington Post, Miami Herald and The New York Times contributed.